Irvine, California Clinical Trials

A listing of Irvine, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)

Research Site
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
A Study Evaluating JUV DERM VOLUMA XC Injectable Gel for Correction of Temple Hollowing in Adult Participants Over 22 Years Old

The objectives of this study are to evaluate the safety and effectiveness of Juvederm Voluma XC injectable gel in adult participants seeking correction of temple hollowing

Steve Yoelin M.D. Medical Associates, Inc.
 (7.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +14 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
fitusiran
antihemophilic factor
bethesda assay
hemophilia
Investigational Site Number 8400010
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

antihemophilic factor
fitusiran
hemarthrosis
hemophilia
haemophilia a
Investigational Site Number 8400016
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +43 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

factor ix
fitusiran
antihemophilic factor
bethesda assay
hemophilia
Investigational Site Number 8400010
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
None

University of Southern California
 (7.6 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400015
 (7.5 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

dulaglutide
cardiovascular disease
tirzepatide
body mass index
Diabetes Associates Medical Group
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +650 other locations
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

alzheimer's disease
positron emission tomography
mini-mental state examination
flortaucipir
florbetapir
Irvine Clinical Research Center
 (0.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +85 other locations
None

University of Southern California
 (7.6 away) Contact site
  • 0 views
  • 19 May, 2025
  • +12 other locations